BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld Asia
Home
» South Korea's GI Innovation secures $31M in series B round for microbiome work
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
South Korea's GI Innovation secures $31M in series B round for microbiome work
Oct. 2, 2019
By
Jihyun Kim
No Comments
HONG KONG – GI Innovation Inc., a microbiome combination drug developer based in Seoul, South Korea, has recently issued fully paid convertible preferred stock (CPS) worth KRW37.5 billion (US$31 million) for a series B investment.
BioWorld Asia
Financings
Microbiome
Series B
Asia-Pacific